DK2844256T3 - Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer - Google Patents

Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer Download PDF

Info

Publication number
DK2844256T3
DK2844256T3 DK13784480.9T DK13784480T DK2844256T3 DK 2844256 T3 DK2844256 T3 DK 2844256T3 DK 13784480 T DK13784480 T DK 13784480T DK 2844256 T3 DK2844256 T3 DK 2844256T3
Authority
DK
Denmark
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
lateral sclerosis
amyotrophic lateral
Prior art date
Application number
DK13784480.9T
Other languages
English (en)
Inventor
Charbel Moussa
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of DK2844256T3 publication Critical patent/DK2844256T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK13784480.9T 2012-05-02 2013-05-02 Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer DK2844256T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641441P 2012-05-02 2012-05-02
US201361771515P 2013-03-01 2013-03-01
PCT/US2013/039283 WO2013166295A1 (en) 2012-05-02 2013-05-02 Treating neural disease with tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2844256T3 true DK2844256T3 (da) 2023-03-27

Family

ID=49514887

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13784480.9T DK2844256T3 (da) 2012-05-02 2013-05-02 Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer

Country Status (7)

Country Link
US (4) US9474753B2 (da)
EP (2) EP4238566A1 (da)
AU (5) AU2013256227B2 (da)
CA (3) CA3134922A1 (da)
DK (1) DK2844256T3 (da)
ES (1) ES2943113T3 (da)
WO (1) WO2013166295A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166295A1 (en) * 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US9393244B2 (en) * 2013-03-15 2016-07-19 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor
WO2015103026A2 (en) * 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
EP3246046A4 (en) * 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US20180311236A1 (en) * 2015-10-28 2018-11-01 Ab Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
WO2017212420A1 (en) * 2016-06-07 2017-12-14 Centre For Cellular And Molecular Platforms Methods and compositions for managing neuroinflammation and neurodegeneration
TW201808294A (zh) * 2016-08-01 2018-03-16 南韓商一洋藥品股份有限公司 用於預防或治療神經退化性疾病之醫藥組成物
US20190262323A1 (en) * 2016-10-31 2019-08-29 Georgetown University Compositions and methods for treating neurodegenerative disorders
WO2018216705A1 (ja) * 2017-05-23 2018-11-29 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
WO2019028298A1 (en) * 2017-08-03 2019-02-07 Truong Daniel Dung USE OF TYROSINE KINASE ABELSON INHIBITOR IN THE TREATMENT OF MULTISYSTEMIZED ATROPHY
JP2021500331A (ja) * 2017-10-19 2021-01-07 エリシウム ヘルス，インコーポレーテッド Ｔｄｐ−４３関連疾患の予防及び治療
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
CN111803505A (zh) * 2019-04-10 2020-10-23 云南帕精生物科技有限公司 尼洛替尼应用于治疗帕金森病
BR112021024835A2 (pt) * 2019-06-11 2022-01-18 Sun Pharma Advanced Res Co Ltd Tratamento para sinuclenopatias
US20220291240A1 (en) * 2019-08-27 2022-09-15 The Johns Hopkins University Biomarkers for neurodegenerative disorders
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501887A (ja) 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
US7496357B2 (en) * 2002-03-04 2009-02-24 At&T Intellectual Property I, L.P. Automated telephone assistant device and associated methods
WO2004000313A2 (fr) 2002-06-24 2003-12-31 Exonhit Therapeutics Sa Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1794313B1 (en) * 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
US7947652B2 (en) 2004-09-03 2011-05-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating PGC-1α to treat huntington's disease
JP2009506302A (ja) * 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
WO2007122634A2 (en) * 2006-04-24 2007-11-01 Jubilant Biosys Limited Pyrimidinediones as tyrosine kinase inhibitors
JP2010527614A (ja) * 2007-05-21 2010-08-19 エラン・フアルマ・インターナシヨナル・リミテツド パーキン基質およびアッセイ
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8618063B2 (en) * 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
WO2009147009A2 (en) 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US8993615B2 (en) 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
KR20120099650A (ko) 2009-10-23 2012-09-11 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CA2788835A1 (en) * 2010-02-05 2011-08-11 The Administrators Of The Tulane Educational Fund The use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes
EP2578590B1 (en) 2010-05-26 2017-08-16 Korea Institute of Science and Technology Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
AU2012208388C1 (en) 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
WO2013166295A1 (en) * 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2015051152A1 (en) 2013-10-03 2015-04-09 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CA3056348A1 (en) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide

Also Published As

Publication number Publication date
AU2023216850B2 (en) 2026-04-09
US10709704B2 (en) 2020-07-14
AU2019203924B2 (en) 2020-09-10
US20220249481A1 (en) 2022-08-11
US20170216287A1 (en) 2017-08-03
AU2017228648B2 (en) 2019-03-07
AU2013256227A1 (en) 2014-11-27
US9474753B2 (en) 2016-10-25
CA3134922A1 (en) 2013-11-07
AU2023216850A1 (en) 2023-09-07
WO2013166295A1 (en) 2013-11-07
AU2013256227B2 (en) 2017-06-15
CA2911040C (en) 2021-11-16
AU2017228648A1 (en) 2017-10-05
US20200405717A1 (en) 2020-12-31
EP2844256B1 (en) 2023-02-22
EP2844256A1 (en) 2015-03-11
AU2019203924A1 (en) 2019-06-20
EP2844256A4 (en) 2016-08-10
AU2020286230B2 (en) 2023-05-18
EP4238566A1 (en) 2023-09-06
AU2020286230A1 (en) 2021-01-07
ES2943113T3 (es) 2023-06-09
CA2911040A1 (en) 2013-11-07
CA3248621A1 (en) 2025-07-09
US20150087653A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
IL288009A (en) Use of inhibitors of bruton's tyrosine kinase (btk)
IL230561A0 (en) Inhibitors of bruton's tyrosine kinsae
EP2858500A4 (en) BRUTON TYROSINE KINASE HEMMER
BR112014000653A2 (pt) inibidores de tirosina quinase de bruton
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
HUE039897T2 (hu) Pirimidinil tirozin kináz inhibitorok
DK3027618T3 (da) Polymorf af syk-hæmmere
IL244492A0 (en) Broton tyrosine kinase inhibitors
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3321262T3 (da) Serin-/threoninkinasehæmmere
DK3003309T3 (da) Behandling af cancer med PI3-kinase-isoform modulatorer
DK2872491T3 (da) Inhibitorer af fibroblastvækstfaktorreceptoren
DK2782570T3 (da) Heterocykliske hæmmere af glutaminase
HRP20170112T8 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
DK2906580T3 (da) Behandling af amyotrofisk lateral sklerose
DK2968208T3 (da) Behandling af kataplexi
CO6970602A2 (es) Inhibidores de quinasa
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
DK2920168T3 (da) Heterocykliske glutaminase-inhibitorer
DK2825175T3 (da) Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
DK2833884T3 (da) Anvendelse af ccr3-inhibitorer